CorMetrix

CorMetrix Inc

0 Investors

Biopharmaceuticals

BEAVERTON, OR

CorMedix Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapeutic products aimed at preventing and treating severe diseases. The company's primary focus lies in reducing infections among vulnerable patient populations, particularly those undergoing hemodialysis.

Products & Team

DefenCath®

Medical DeviceSeed

DefenCath is a novel, first-in-class, non-antibiotic antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections (CRBSIs) in adult patients with kidney failure undergoing chronic hemodialysis. It is FDA approved and aimed at providing a safe alternative to antibiotic locks.

Value Proposition

DefenCath specifically addresses the critical issue of CRBSIs, providing a solution that mitigates the risk of life-threatening infections in vulnerable patients without fostering antibiotic resistance.

Pain Points

High morbidity and mortality rates associated with catheter-related infections.

First-in-class non-antibiotic antimicrobial solutionFDA approved for reducing CRBSIsEstablished reimbursement pathways for inpatient and outpatient use10 years of market exclusivity as a New Chemical Entity